P739 Translating Pharmacokinetic and Efficacy Outcomes of NLRX1 Agonist NX-13: Contrasting a Pig Model and a Human Phase 1b Clinical Trial in Ulcerative Colitis

B Siegmund,B Verstockt,M Dubinsky,R Mosig,F Cataldi,S Danese,A Yarur

DOI: https://doi.org/10.1093/ecco-jcc/jjad212.0869

2024-01-01

Journal of Crohn's and Colitis

Abstract:Abstract Background In rodent models of ulcerative colitis (UC), NX-13 (as an orally active, gut selective NLRX1 agonist) improves disease activity through a novel bimodal mechanism. Subsequently, a pig DSS colitis experiment was performed to generate pharmacokinetic (PK) and mechanistic insights, given pigs can be dosed with tablets and their gastrointestinal physiology, microbiome, and immune system is markedly more similar to humans than rodents are. We here describe the efficacy and PK of NX-13 tablets in pigs compared to phase 1 clinical trials. Methods NX-13 immediate release (IR) tablets were used in pig studies and human clinical trials with plasma samples collected at hourly intervals. Stool samples were collected at ~24hrs after last dose. NX-13 phase 1 clinical trials were double blind, randomized and placebo-controlled studies testing multiple IR doses in healthy subjects (1a) or subjects with active UC (1b) 1,2. NX-13 concentrations were determined by LC-MS/MS and linear regression to standard curve. Results In pigs, oral NX-13 treatment dampened colitis development with differences as early as day 2, becoming significant at days 4-6 (Fig. 1A). Consistent results were observed in the human Phase 1b trial, including fast rectal bleeding improvement as early as week 2 (Fig. 1B) and endoscopic improvement at week 4. Nonetheless, the NX-13 PK characteristics differed between pigs and humans. Firstly, NX-13’s low level of systemic exposure peaked 1 hour after dosing in the human studies, whereas Tmax in pigs was 7 hours at comparable doses. Secondly, the portion of NX-13 retained in the stool is greater in pigs (250-1000 times greater than plasma levels), compared to humans (150-400 times greater) although both stool and plasma concentrations were greater in pigs (Fig. 1C). This suggests NX-13 is not gut-restricted in humans, but rather gut-selective with low systemic absorption. Interestingly, the stool:plasma ratio was numerically lower in patients with UC compared to normal healthy volunteers (Figure 1C), implying epithelial barrier integrity may affect absorption. Despite these differences in PK characteristics, we see similarly fast onset of action signals in the pig model and the human phase Ib trial, suggesting that sufficient target engagement is achieved locally in both species. Conclusion NX-13, a novel NLRX1 agonist, has a low percentage of drug absorbed systemically in both pigs and humans, although there are species specific differences in absorption patterns. The hypothesis of a gut-selective compound with low systemic absorption and PK characteristics of NX-13 will be analyzed in the ongoing NEXUS phase 2 study in patients with moderate to severe UC. 1 Leber et al. UEG J (9) Supp. 2 Peyrin-Biroulet, et al. JCC (17) Supp.

gastroenterology & hepatology